Floatz logo

Itacitinib

T-Cell Prolymphocytic Leukemia

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the T-Cell Prolymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 2BB
Cyclophosphamide
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2BB
Fludarabine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB

View all 28 →

Same molecule, other indications

Itacitinib is also rated in:

cancerDormant
CCC
Indicative ·
51 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →